A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

Metastatic triple-negative breast cancer is an aggressive cancer with limited treatment options. Sacituzumab govitecan is a potential new treatment for people with metastatic triple-negative breast cancer that has been studied in the ASCENT clinical study.

This new article, published in Future Oncology, provides a plain language summary of the ASCENT study. The article, called ‘A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer’ can be read for free here.

The original article published in New England Journal of Medicine can be read here.

• antibody–drug conjugate
• breast cancer
• sacituzumab govitecan
• triple-negative breast cancer
• Trop-2